55408-14-5

Upstream product

• 186581-53-3 diazomethane 
• 55408-11-2 5-chloromethyl-1H-tetrazole 
• 55408-11-2 5-(chloromethyl)-2H-1,2,3,4-tetrazole 

Downstream Products

• 55408-47-4 2-methyl-2H-tetrazole-5-carbaldehyde 
• 1280294-13-4 C₁₄H₁₈N₄O₅ 

Relevant academic research and scientific papers

High affinity phenylglycinol-based NK1 receptor antagonists

Heterocyclic replacements for the carboxamido group of the previously disclosed phenylglycinol-based human NK1 (hNK1) receptor antagonists have been investigated, ultimately leading to acyclic compounds with sub-nanomolar affinity for the hNK1 receptor.

NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME

Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R4 is —(CH2)n-Z-(CH2)m—PO(OR7)(OR8), —(CH2)nZ-(CH2)m—PO(OR7)Rg, —(CH2)n-Z-(CH2)m—OPO(OR7)Rg, —(CH2)nZ—(CH2)m—OPO(R9)(R10), or —(CH2)nZ—(CH2)m—PO(R9)(R10);R5 and R6 are independently selected from H, alkyl and halogen;Y is R7(CH2)s or is absent; andX, n, Z, m, R4, R5, R6, R7, and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.